Search results for "connective tissue disease"

showing 10 items of 874 documents

Hereditary Angioedema with Normal C1 Inhibitor Activity Including Hereditary Angioedema with Coagulation Factor XII Gene Mutations

2006

Recurrent angioedema of the skin is a commonly diagnosed clinical symptom that can be found in various clinical entities [1,2]. Some types of angioedema of the skin are associated with episodes of upper airway obstruction that may be life threatening. Death by asphyxiation from laryngeal edema is well known in hereditary angioedema (HAE) due to C1 inhibitor deficiency [3,4] and in recurrent angioedema induced by angiotensinconverting enzyme (ACE) inhibitors [5–9]. Therefore, it is important to determine the exact type of angioedema in each patient. In many patients angioedema is associated with urticaria. If relapsing urticaria occurs simultaneously or alternately with angioedema, both cond…

MaleAllergymedicine.medical_specialtyImmunologyGene mutationLaryngeal EdemaC1-inhibitorimmune system diseasesHumansImmunology and AllergyMedicinecardiovascular diseasesAngioedemaskin and connective tissue diseasesAspirinAngioedemabiologybusiness.industryfood and beveragesmedicine.diseaseDermatologyPedigreeFactor XIIMutationImmunologyHereditary angioedemaSerum sicknessbiology.proteinFemalemedicine.symptombusinessComplement C1 Inhibitor Proteinmedicine.drugImmunology and Allergy Clinics of North America
researchProduct

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

2010

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated. ©…

MaleAntibodieReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptRandomized controlled triallawimmune system diseasesOutcome Assessment Health CareMonoclonalImmunology and Allergyskin and connective tissue diseasesAntirheumatic AgentAntibodies MonoclonalAntirheumatic AgentsTreatment OutcomeAntirheumatic AgentsFemalemedicine.drugHumanReceptormusculoskeletal diseasesAdultAnkylosingmedicine.medical_specialtyImmunologyDrug Administration ScheduleOutcome Assessment (Health Care)RheumatologyInternal medicinemedicineHumansSpondylitis AnkylosingSpondylitisSpondylitiAnkylosing spondylitisbusiness.industryTumor Necrosis Factor-alphaAnkylosing spondylitis; Etanercept; Infliximab; Adult; Antibodies Monoclonal; Antirheumatic Agents; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Male; Outcome Assessment (Health Care); Receptors Tumor Necrosis Factor; Spondylitis Ankylosing; Treatment Outcome; Tumor Necrosis Factor-alpha; Rheumatology; Immunology; Immunology and Allergymedicine.diseaseInfliximabRheumatologyInfliximabClinical trialAnkylosing spondylitistomatognathic diseasesImmunoglobulin GPhysical therapybusinessTumor Necrosis Factor
researchProduct

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

2018

International audience; Objective - To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides. Methods - The 28-month Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis trial compared rituximab with azathioprine to maintain remission in patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis or renal-limited ANCA-associated vasculitis. Thereafter, prospective patient follow-up lasted until month 60. The primary endpoint was the major-relapse rate at month 60. Relapse and serious adverse event-free …

MaleAzathioprineKaplan-Meier Estimateurologic and male genital diseasesGastroenterologySeverity of Illness Index0302 clinical medicineimmune system diseasesRecurrenceRisk FactorsAzathioprineClinical endpointImmunology and Allergy030212 general & internal medicineskin and connective tissue diseasestreatmentRemission InductionMiddle Aged3. Good healthTreatment OutcomeAntirheumatic AgentsRituximabFemalesystemic vasculitisGranulomatosis with polyangiitisMicroscopic polyangiitisVasculitisRituximabImmunosuppressive Agentsmedicine.drugSystemic vasculitisAdultmedicine.medical_specialtyImmunologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGeneral Biochemistry Genetics and Molecular BiologyDrug Administration ScheduleAntibodies Antineutrophil Cytoplasmic03 medical and health sciencesRheumatologyInternal medicinemedicineHumanscardiovascular diseasesLymphocyte CountGlucocorticoidsAnti-neutrophil cytoplasmic antibodyAged030203 arthritis & rheumatology[SDV.GEN]Life Sciences [q-bio]/Geneticsgranulomatosis with polyangiitisDose-Response Relationship Drugbusiness.industrymedicine.diseaserespiratory tract diseases[ SDV.GEN ] Life Sciences [q-bio]/GeneticsbusinessAnnals of the rheumatic diseases
researchProduct

Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy

2015

Increasing evidence indicates that common genetic variants may contribute to the heritable risk of breast cancer (BC). In this study, we investigated whether single nucleotide polymorphisms (SNPs), within the 8q24.21 multi-cancer susceptibility region and within BC-associated loci widespread in the genome, may influence the risk of BC in men, and whether they may be associated with specific clinical-pathologic characteristics of male BC (MBC). In the frame of the ongoing Italian Multicenter Study on MBC, we performed a case-control study on 386 MBC cases, including 50 BRCA1/2 mutation carriers, and 1105 healthy male controls, including 197 unaffected BRCA1/2 mutation carriers. All 1491 subj…

MaleCancer ResearchPredictive Value of Test8q24.21; BRCA1/2; Clinical-pathologic characteristics; Low-penetrance BC alleles; Male breast cancer; SNPs; BRCA1 Protein; BRCA2 Protein; Biomarkers Tumor; Breast Neoplasms Male; Case-Control Studies; Chi-Square Distribution; Gene Frequency; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Italy; Linear Models; Logistic Models; Male; Multivariate Analysis; Mutation; Odds Ratio; Phenotype; Predictive Value of Tests; Risk Factors; Chromosomes Human Pair 11; Chromosomes Human Pair 14; Chromosomes Human Pair 8; Chromosomes Human Pair 9; Polymorphism Single Nucleotide; Oncology; Cancer ResearchGene FrequencyRisk FactorsGenotypeOdds RatioMedicineskin and connective tissue diseasesMultivariate AnalysiSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAGeneticsClinical-pathologic characteristicsBRCA1 ProteinClinical-pathologic characteristicHomozygoteLow-penetrance BC allelesPhenotype8q24.21OncologyItalyMale breast cancer8q24.21; BRCA1/2; Clinical-pathologic characteristics; Low-penetrance BC alleles; Male breast cancer; SNPs; Cancer Research; OncologyLinear ModelCase-Control StudieChromosomes Human Pair 9HumanChromosomes Human Pair 8SNPsHeterozygoteLogistic ModelSNPSingle-nucleotide polymorphismPolymorphism Single NucleotideBreast Neoplasms MaleBreast cancerPredictive Value of TestsBRCA1/2Biomarkers TumorSNPHumansGenetic Predisposition to DiseaseAllele frequencyBRCA2 ProteinChromosomes Human Pair 14Chi-Square Distributionbusiness.industryRisk FactorChromosomes Human Pair 11Case-control studyOdds ratiomedicine.diseaseMale breast cancerLogistic ModelsCase-Control StudiesMultivariate AnalysisMutationLinear ModelsbusinessLow-penetrance BC allele
researchProduct

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model

2008

Trastuzumab (Herceptin) has improved therapy of breast cancer. Only patients overexpressing ERBB2 are treated with trastuzumab, whereas its use in tumours without ERBB2 expression is useless. This led to the concept that the subgroup of trastuzumab-sensitive tumours is ‘ERBB2-dependent', meaning that ERBB2 signalling is indispensable for growth of these tumours. We used a mouse model that allows anhydrotetracycline (ATc)-controlled downregulation of ERBB2 in tumour tissue. ERBB2 mRNA and protein expression were downregulated below detection limit leading to a macroscopically complete tumour remission within 14 days. Tumour remission was accompanied by a strong decrease in proliferation, a m…

MaleCancer ResearchReceptor ErbB-2AKT1AKT2ApoptosisMiceTrastuzumabPKBskin and connective tissue diseasesERBB2Mitogen-Activated Protein Kinase 3biologyERK1/2herceptinAntibodies MonoclonalCytochromes cImmunohistochemistrynude miceGene Expression Regulation NeoplasticOncologyTetracyclinesKi-67Ki-67Femalemedicine.drugmedicine.medical_specialtyBlotting WesternDown-RegulationMice NudeAntineoplastic AgentsProtein Serine-Threonine KinasesAntibodies Monoclonal Humanizedresistance3-Phosphoinositide-Dependent Protein Kinasesbreast cancerDownregulation and upregulationresponse to therapyInternal medicineHER2medicineAnimalsRNA Messengercytochrome c releaseProtein kinase Bneoplasmstumour developmentCell Proliferationhumanised monoclonal antibodyAktCancerMammary Neoplasms ExperimentalTrastuzumabmedicine.diseaseEndocrinologyKi-67 AntigenApoptosisDrug Resistance Neoplasmbiology.proteinCancer researchreceptor tyrosine kinaseTranslational TherapeuticsProto-Oncogene Proteins c-aktBritish Journal of Cancer
researchProduct

BRAF(V600E) MUTATION AND THE BIOLOGY OF PAPILLARY THYROID CANCER

2008

BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers. We evaluated the relationship between BRAF((V600E)) and tumor, host, and environmental factors in PTCs from all geographical areas of Sicily. By PCR, BRAF((V600E)) was investigated in a series of 323 PTCs diagnosed in 2002-2005. The correlation between clinicopathological tumor, host, and environmental characteristics and the presence of BRAF((V600E)) were evaluated by both univariate and multivariate analyses. BRAF((V600E)) was found in 38.6% PTCs, with a 52% frequency in the classical PTCs and 26.4% in the tall cell variant. Univariate analysis indi…

MaleCancer Researchendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.disease_causethyroidPapillary thyroid cancerSettore MED/13 - EndocrinologiaImmunoenzyme TechniquesEndocrinologythyroid cancerskin and connective tissue diseasesSicilyMicrodissectionBRAF(V600E)Univariate analysisMutationGeographyReverse Transcriptase Polymerase Chain ReactionThyroidBRAF V600; Papillary Thyroid CancerMiddle Agedhumanitiesmedicine.anatomical_structureMatrix Metalloproteinase 9OncologyLymphatic MetastasisDisease ProgressionFemaleMicrodissectionProto-Oncogene Proteins B-rafPapillary thyroid cancer BRAF(V600E) thyroid thyroid cancerBRAF V600BiologyThyroid carcinomamedicineCarcinomaHumansNeoplasm InvasivenessRNA MessengerThyroid NeoplasmsneoplasmsDNA PrimersLasersPapillary thyroid cancer BRAFmedicine.diseaseCarcinoma Papillarydigestive system diseasesMutationCancer researchV600EFollow-Up StudiesPapillary Thyroid Cancer
researchProduct

Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy

2012

Pancreatic adenocarcinoma (PC) is the third most common cancer associated with BRCA mutations. Most notice has been given to BRCA2, while the association between BRCA1 and PC is less widely reported. Recently, PALB2 has been implicated in both PC and breast cancer (BC) susceptibility. We selected 29 Italian PC patients from a case-control study of PC according to their personal and family history of both PC and breast/ovarian cancer (BC/OC) and tested them for presence of germline mutations in BRCA1, BRCA2 and PALB2. We identified no germline mutations or deletions in PALB2, but detected 7 BRCA mutations (4 in BRCA1 and 3 in BRCA2). These findings suggest that PALB2 does not play a major ro…

MaleCancer Researchendocrine system diseasesSettore MED/06 - Oncologia MedicaBRCAGermlineGermline mutationHereditary breast ovarian cancer syndrome (HBOC)skin and connective tissue diseasesGenetics (clinical)Nuclear ProteinOvarian NeoplasmsAged 80 and overGeneticseducation.field_of_studyBRCA1 ProteinPancreatic NeoplasmNuclear ProteinsMiddle Agedfemale genital diseases and pregnancy complicationsPedigreeItalyOncologyAdenocarcinomaFemaleCase-Control StudieFanconi Anemia Complementation Group N ProteinPancreatic cancer susceptibility; BRCA; PALB2; Hereditary breast ovarian cancer syndrome (HBOC); Germline mutationBreast NeoplasmHumanAdultPALB2PopulationBreast NeoplasmsAdenocarcinomaGermline mutationBreast cancerGeneticPancreatic cancerGeneticsmedicineHumansGenetic Predisposition to DiseaseeducationGerm-Line MutationAgedBRCA2 ProteinTumor Suppressor Proteinbusiness.industryTumor Suppressor ProteinsOvarian NeoplasmCancermedicine.diseasePancreatic cancer susceptibilityPancreatic NeoplasmsCase-Control StudiesPALB2businessGene DeletionFamilial Cancer
researchProduct

Knockout of the KH-Type Splicing Regulatory Protein Drives Glomerulonephritis in MRL-Faslpr Mice

2021

KH-type splicing regulatory protein (KSRP) is an RNA-binding protein that promotes mRNA decay and thereby negatively regulates cytokine expression at the post-transcriptional level. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by dysregulated cytokine expression causing multiple organ manifestations

MaleChemokineMice Inbred MRL lprQH301-705.5medicine.medical_treatmentLupus nephritisBiologyKidneyArticleImmune systemsystemic lupus erythematosusimmune system diseasesmedicinecytokineAnimalsCD11a AntigenRNA MessengerKSRPBiology (General)skin and connective tissue diseasesRegulation of gene expressionMice KnockoutSystemic lupus erythematosusFOXP3RNA-Binding ProteinsGlomerulonephritisGeneral Medicinemedicine.diseaseMice Inbred C57BLCytokineCancer researchbiology.proteinTrans-ActivatorsFemaleLymph NodesChemokinesBiomarkersglomerulonephritispost-transcriptional regulationCells
researchProduct

Complete congenital heart block is associated with increased autoantibody titers against calreticulin.

1996

Complete congenital heart block (CCHB) is associated with anti-Ro/SS-A and anti-La/SS-B antibodies. Calreticulin, a calcium-binding, multi-functional protein of the endoplasmic reticulum with C-terminal KDEL-sequence, is not part of the Ro/SS-A ribonucleoprotein complex. In this study anti-calreticulin autoantibody responses in serum samples from 18 infants with CCHB, their mothers and in a control group of 11 anti-Ro/SS-A or anti-La/SS-B positive infants without heart block and their mothers were analysed. Specific enzyme-linked immunosorbent assays were performed. Nine out of 18 sera with CCHB contained IgG anti-calreticulin antibodies. Four sera of those with IgG antibodies also had IgM …

MaleClinical BiochemistryBlotting WesternEnzyme-Linked Immunosorbent AssayBiochemistryAutoantigensImmunopathologymedicineHumansNeonatal lupus erythematosusAutoantibodiesAutoimmune diseaseLupus erythematosusbiologybusiness.industryCalcium-Binding ProteinsAutoantibodyInfant NewbornGeneral Medicinemedicine.diseaseConnective tissue diseaseHeart BlockImmunoglobulin MRibonucleoproteinsImmunoglobulin GImmunologybiology.proteinFemaleAntibodybusinessCalreticulinCalreticulinEuropean journal of clinical investigation
researchProduct

Disentangling effects of auditory distraction and of stimulus-response sequence

2009

When we pay attention to one task, irrelevant changes may interfere. The effect of changes on behavioral and electrophysiological responses has been studied in two separate research fields: Research on Distraction states that a rare irrelevant change takes attention away from the primary task. Research on Sequences states that any change in stimulus or response incurs a cost or benefit depending on the kind of change. To disentangle distraction from sequence effects, we made task-irrelevant changes rare in one condition and frequent in another while also assessing stimulus and response changes from trial to trial. Participants used key presses to classify syllables presented in two differen…

MaleCognitive NeurosciencePoison controlExperimental and Cognitive PsychologyStimulus (physiology)Electroencephalographybehavioral disciplines and activitiesAuditory distractionYoung AdultP3aStimulus–response modelDevelopmental NeuroscienceDistractionP3bReaction TimemedicineHumansAttentionskin and connective tissue diseasesEvoked PotentialsBiological Psychiatrymedicine.diagnostic_testEndocrine and Autonomic SystemsGeneral NeuroscienceElectroencephalographyhumanitiesNeuropsychology and Physiological PsychologyAcoustic StimulationNeurologySpeech PerceptionFemalesense organsPsychologySocial psychologyPsychomotor Performancepsychological phenomena and processesCognitive psychologyPsychophysiology
researchProduct